"Our vision is to lead in targeted therapies for aldosterone-driven cardio-renal-metabolic (CRM) disease. By targeting aldosterone dysregulation, we aim to meet a critical unmet need with a new mechanism in a field that has seen little innovation in over two decades." -Jon Congleton CEO of Mineralys Therapeutics

In just 6 years, Mineralys advanced #lorundrostat, a potential first-in-class aldosterone synthase inhibitor, from concept to pivotal published trials in #hypertension and is now preparing for a pre-NDA meeting in Q4 2025.

Learn more: www.thepharmaletter.com/pharmaceutic...

#Innovation #MLYS

Lorundrostat for Adults With Uncontrolled and Treatment-Resistant Hypertension This randomized clinical trial compares the efficacy and safety of lorundrostat for lowering blood pressure when added to a prescribed antihypertensive regimen of 2 to 5 medications vs placebo among p...

Lorundrostat, inhibidor de la aldosterona sintasa, reduce la presión arterial en adultos con hipertensión no controlada, incluyendo los que tienen hipertensión resistente al tratamiento, con un perfil de seguridad aceptable #hypertension #lorundrostat jamanetwork.com/journals/jam...

Lorundrostat lowers BP in patients with uncontrolled, resistant hypertension Lorundrostat reduces systolic blood pressure more than placebo over 6 weeks of treatment in people with uncontrolled or treatment-resistant hypertension.

#MedNews - Lorundrostat reduces systolic blood pressure more than placebo over 6 weeks of treatment in people with uncontrolled or treatment-resistant #hypertension.

Full story 👉 buff.ly/zlqzC1Y

#CardioSky #Lorundrostat

Tomorrow, on #NephJC we discuss the @nejm.org trial on #lorundrostat in uncontrolled hypertension

Lorundrostat Efficacy and Safety in Patients with Uncontrolled Hypertension | NEJM Aldosterone dysregulation contributes to hypertension. Lorundrostat is an aldosterone synthase inhibitor, but data on its efficacy and safety in patients with hypertension are limited. In this mult...

The ASIs have arrived

www.nejm.org/doi/full/10....

Aldosterone synthase inhibitors - first one to finish the phase 3 line

#Lorundrostat #Hypertension

A 💫 finding of run-in phase of #ADVANCE-HTN Ph2b #RCT:
64% ppl with “uncontrolled” #hypertension got BP control in 3 wks through standard genericTx

#Aldosterone synthase blocker #lorundrostat 50 mg ⬇️BP at 8wks (w ⬆️K). 100mg: no evidence of added benefit
#ACC25
www.radcliffecvrm.com/video-index/...

And side effects seem to be mild although there was hyperkaliemia and also hyponatriemia.
#acc25 #hypertension #lorundrostat

Breaking: Lorundrostat an aldosterone synthase inhibitor showed about 15 mmHg decrease on top of background anthypertensive medication
#acc25 #hypertension #lorundrostat

And side effects seem to be mild although there was hyperkaliemia and also hyponatriemia.
#acc25 #hypertension #lorundrostat

Breaking: Lorundrostat an aldosterone synthase inhibitor showed about 15 mmHg decrease on top of background anthypertensive medication
#acc25 #hypertension #lorundrostat

#PortfolioNews | Our #quoted company Mineralys Therapeutics (Nasdaq: #MLYS) reports #positive Phase 3 & 2 results for #lorundrostat in #hypertension & announces a $250M #PublicOffering to advance R&D!

👉 buff.ly/qeyUu5K
👉 buff.ly/g18zKmA

#ClinicalTrials

Mineralys Therapeutics Completes Enrollment – Ysios Capital Continues to anticipate announcing topline data from Explore-CKD trial in Q2 2025

#PortfolioNews I Our #quoted #portfolio company #Mineralys #MLYS completed Enrollment in Explore-CKD Phase 2 Trial of #Lorundrostat for the Treatment of #Hypertension in Subjects with Stage 2 to 3b chronic kidney disease #CKD and #Albuminuria

👉 https://buff.ly/4gqM4t2

#vc #ClinicalTrials